Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301169 | 0.89 | PPARG (0.84) | PPARGHDAC1HDAC6RORCHDAC3 | |
| SCHEMBL6301327 | 0.88 | PPARG (0.83) | PPARGHDAC1HDAC6RORCAGTR1 | |
| SCHEMBL6308137 | 0.88 | PPARG (0.83) | PPARGHDAC1HDAC6RORCAGTR1 | |
| SCHEMBL7650777 | 0.87 | PPARG (0.91) | PPARGHDAC1HDAC6RORCIRAK4 | |
| SCHEMBL6301610 | 0.87 | PPARG (0.81) | PPARGHDAC1HDAC6RORCAGTR1 | |
| SCHEMBL6134679 | 0.87 | PPARG (0.81) | PPARGHDAC1HDAC6RORCAGTR1 | |
| SCHEMBL6472946 | 0.86 | PPARG (0.79) | PPARGHDAC1HDAC6RORCHDAC3 | |
| SCHEMBL1160303 | 0.86 | PPARG (0.82) | PPARGHDAC1HDAC6RORCIRAK4 | |
| SCHEMBL6303482 | 0.85 | PPARG (0.79) | PPARGHDAC1HDAC6RORCAGTR1 | |
| SCHEMBL7650594 | 0.85 | PPARG (0.78) | PPARGHDAC1HDAC6RORCAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073171-A1 | DRUG DELIVERY SYSTEM FOR THE TREATMENT OF FEMALE SEXUAL INTEREST AND AROUSAL DISORDER | Freya Pharma Solutions Holding B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| US-12186322-B2 | Liquid oral formulations for tadalafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-01-07 | — | — | US | disclosed |
| US-12186321-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-01-07 | — | — | US | disclosed |
| US-20240299396-A1 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-20240245688-A1 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-07-25 | — | — | US | disclosed |
| US-20240245689-A1 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-07-25 | — | — | US | disclosed |
| US-12005062-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-06-11 | — | — | US | disclosed |
| US-20240165032-A1 | DRUG DELIVERY SYSTEM | EB IP HYBRITABS B V (NL) | 2024-05-23 | — | — | US | disclosed |
| US-11975006-B2 | Liquid oral formulations for tadalafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-20230381187-A1 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230330028-A1 | PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS | EB IP HYBRITABS B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-11759468-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-09-19 | — | — | US | disclosed |
| US-20230285398-A1 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| US-11666576-B2 | Liquid oral formulations for tadalafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2023-06-06 | — | — | US | disclosed |
| US-20220409621-A1 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| CN-109414402-B | Method for preparing a drug delivery system with a testosterone compound present externally or topically and such a drug delivery system | EB IP希博里塔布斯有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11464778-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
| US-20220296602-A1 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| US-11382917-B2 | Liquid oral formulations for tadalafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-07-12 | — | — | US | disclosed |
| US-11337979-B2 | Liquid oral formulations for sildenafil | LIQMEDS WORLDWIDE LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |